Hospital-acquired infections: diseases with increasingly limited therapies.
about
FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testisAntimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridoneIn vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid IIBiological activities of retro and diastereo analogs of a 13-residue peptide with antimicrobial and hemolytic activities.Genomics and antimicrobial drug discovery.A modern-day purgatory: older adults in the emergency department with nonoperative injuries.VanX, a bacterial D-alanyl-D-alanine dipeptidase: resistance, immunity, or survival function?Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumanniiInteractions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistanceDevelopment of the intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term infants.Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitalsCoenzyme A disulfide reductase, the primary low molecular weight disulfide reductase from Staphylococcus aureus. Purification and characterization of the native enzyme.Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA bindingNovel targets for the future development of antibacterial agents.In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinemPlasmid-encoded MucB protein is a DNA polymerase (pol RI) specialized for lesion bypass in the presence of MucA', RecA, and SSBEcological control of the gastrointestinal tract. The role of probiotic flora.A vancomycin-inducible lacZ reporter system in Bacillus subtilis: induction by antibiotics that inhibit cell wall synthesis and by lysozyme.Low prevalence of gastrointestinal colonization with antimicrobial-resistant bacteria in high risk units in a Canadian tertiary care centre.Antimicrobial resistance risk assessment in food safety.Combating Gram-positive pathogens: emerging techniques to identify relevant virulence targets.In vivo characterization of the type A and B vancomycin-resistant enterococci (VRE) VanRS two-component systems in Escherichia coli: a nonpathogenic model for studying the VRE signal transduction pathwaysEvaluating treatment protocols to prevent antibiotic resistanceRapid single cell detection of Staphylococcus aureus by aptamer-conjugated gold nanoparticlesVancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implicationsRole of bioinformatics in the development of new antibacterial therapy.A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential Lipid II docking interface.Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (Avilamycin and evernimicin).Cloning and characterization of a novel, plasmid-encoded trimethoprim-resistant dihydrofolate reductase from Staphylococcus haemolyticus MUR313.Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli.The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermidis ATCC 14990: the origin of the trimethoprim-resistant S1 DHFR from Staphylococcus aureus?Importance of the E-46-D-160 polypeptide segment of the non-penicillin-binding module for the folding of the low-affinity, multimodular class B penicillin-binding protein 5 of Enterococus hirae.Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12.Lipid A: target for antibacterial drugs.Antimicrobial resistance: Implications for therapy of infections with common childhood pathogens.
P2860
Q24306578-A67CE25F-7D8A-4D9D-ACE1-8E9FF29F3696Q24671956-DEB8D1CE-7E6A-4B35-B246-32C30461D8DFQ28367886-B2EE2151-3706-422E-BC10-BF061816A1FFQ28379217-D40D7417-3115-4770-876B-2A8B5F101142Q28534946-3C07341D-C49C-4A21-9A16-04262A69EC17Q31902860-EFB85A15-C2BA-4F07-B91E-E6646DC83E92Q33537162-B48A3A35-1271-40AA-842C-AD1088BF2BCAQ33555547-CE4D6A27-307F-4925-98C1-EF6250A11BFBQ33740144-B58443E2-AB34-4784-876E-364D77267A30Q33836490-E539CB13-7A96-44E9-BD8D-3E29525D5F3BQ34049982-5705D95D-E774-49A4-87DE-AA1072BC85B4Q34102811-00A3AD0C-B70A-436B-A8B4-A5C2C270F83EQ34203355-6269F623-0B11-4652-9922-F756C252D399Q34340879-7AA57127-EF37-4E1F-8D41-ABE07938042EQ34458896-7929D574-E036-4092-8D01-98D706899209Q34543629-C4D41058-84E2-4A29-B15B-7CD20943DCD1Q34631428-24A45119-DFFA-4DE8-ACE9-50352F228607Q35139480-FB59F179-D67C-4B94-B857-8D431E7AF6A3Q35265889-559E7083-0BFA-4096-A63E-AEF638E7E379Q35348967-876A5659-75D2-4600-9192-6CB00FCA58C9Q35615713-594A5DDB-6A2B-4030-92FA-1E5A25270662Q35891501-B3A2E4BD-37F2-450F-A83B-EBBFD6466364Q35903954-3A6AD1AE-44F7-445B-880B-B96F52CC9F8AQ36181392-0AFA0530-9DD2-45A2-92AA-6D43E928C448Q36327115-6835FE08-DF8E-4498-9DBE-F468A8DB9250Q36637189-0B242889-7539-4D36-95AB-C338CAFC7F37Q36860174-A0BC718C-1BC7-4E35-AE0F-FD615405127CQ37064230-C515924B-3699-4B30-A30B-D94F5158CB0DQ37077624-FE8B3D72-7B32-4762-8D79-F6CD365E7127Q37252733-754C8768-AB36-45B5-BE3E-913A421D4DF3Q37310592-36C73C54-9AF5-491D-B2E5-92F5D3260182Q39475744-3E190B89-4E80-40B5-B097-B5B87ABDA53AQ39780325-9B4BC675-95B8-4EB6-A4FC-CA5C1BF69CE8Q39782423-B77B27F4-B9A1-469F-93B9-682A4A9D3E1FQ39783740-1BC7D68E-2E9C-4B52-9C1F-797490363DF9Q39836899-704F2032-2BF0-49A8-9E35-A49D11F4DEC1Q39840713-CE6DA24D-8EE1-4FD1-BA2C-1DDBBF321D17Q39847254-F76C2ECC-DA4A-4666-9CB3-C3FBA30A2A49Q41269646-5AAA26BA-E357-473D-8EE1-785F175FB337Q42018726-157A3825-07E5-4938-A15E-7C17A559218F
P2860
Hospital-acquired infections: diseases with increasingly limited therapies.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Hospital-acquired infections: diseases with increasingly limited therapies.
@ast
Hospital-acquired infections: diseases with increasingly limited therapies.
@en
type
label
Hospital-acquired infections: diseases with increasingly limited therapies.
@ast
Hospital-acquired infections: diseases with increasingly limited therapies.
@en
prefLabel
Hospital-acquired infections: diseases with increasingly limited therapies.
@ast
Hospital-acquired infections: diseases with increasingly limited therapies.
@en
P2860
P356
P1476
Hospital-acquired infections: diseases with increasingly limited therapies.
@en
P2093
P2860
P304
P356
10.1073/PNAS.91.7.2420
P407
P577
1994-03-01T00:00:00Z